VEOZA is indicated for the treatment of moderate to severe Vasomotor Symptoms (VMS) associated with menopause.1,2
VEOZA directly targets a source of VMS—specific neurons in the hypothalamus. Give your patients another way to treat the heat of VMS day and night.1
MOA
Watch the mechanism of action (MOA)
VEOZA is the first and only selective neurokinin 3 (NK3) receptor antagonist that blocks NKB from binding on KNDy neurons to help reduce heat signals that trigger VMS1,3
KNDy: kisspeptin/neurokinin B/dynorphin, NKB: neurokinin B.
Offer your patients a first-in-class treatment to manage VMS with VEOZA1,3
VMS relief day and night
VEOZA demonstrated statistically significant reductions from baseline in the frequency and severity of moderate to severe VMS over 24 hours compared to placebo, at weeks 4 and 12 1
REFERENCES: 1. VEOZA [Veoza Israeli SmPC] 2. Thurston RC. Vasomotor symptoms. In: Crandall CJ, Bachman GA, Faubion SS, et al., eds. Menopause Practice: A Clinician’s Guide. 6th ed. Pepper Pike, OH: The North American Menopause Society, 2019:43-55. 3. Depypere H, Lademacher C, Siddiqui E, Fraser GL. Fezolinetant in the treatment of vasomotor symptoms associated with menopause. Expert Opin Investig Drugs 2021;30(7):681-94.
